tiprankstipranks
DENTSPLY SIRONA Inc (CH:DY2)
:DY2
Switzerland Market

DENTSPLY SIRONA (DY2) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

DY2 Analyst Ratings

Hold
12Ratings
Hold
2 Buy
9 Hold
1 Sell
Based on 12 analysts giving stock ratings to
DENTSPLY
SIRONA
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

DY2 Stock 12 Month Forecast

Average Price Target

CHF11.35
▲(14.27% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for DENTSPLY SIRONA in the last 3 months. The average price target is CHF11.35 with a high forecast of CHF13.66 and a low forecast of CHF8.84. The average price target represents a 14.27% change from the last price of CHF9.93.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"CHF7","14":"CHF14","8.75":"CHF8.75","10.5":"CHF10.5","12.25":"CHF12.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":13.65616511,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF13.66</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11.34666659875,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF11.35</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.83634213,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF8.84</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,8.75,10.5,12.25,14],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.93,10.216628085384615,10.50325617076923,10.789884256153845,11.07651234153846,11.363140426923076,11.649768512307691,11.936396597692308,12.223024683076922,12.509652768461539,12.796280853846152,13.08290893923077,13.369537024615385,{"y":13.65616511,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.93,10.03897435375,10.1479487075,10.25692306125,10.365897415,10.474871768749999,10.583846122499999,10.69282047625,10.80179483,10.91076918375,11.0197435375,11.12871789125,11.237692245,{"y":11.34666659875,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.93,9.845872471538462,9.761744943076923,9.677617414615385,9.593489886153845,9.509362357692307,9.425234829230769,9.341107300769231,9.256979772307693,9.172852243846155,9.088724715384615,9.004597186923077,8.920469658461538,{"y":8.83634213,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.94,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.94,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.94,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.94,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.94,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.94,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.94,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.94,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.94,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.94,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.94,"date":1780272000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":8.94,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.93,"date":1785542400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetCHF13.66Average Price TargetCHF11.35Lowest Price TargetCHF8.84
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays
CHF7.23CHF8.84
Sell
-11.01%
Downside
Reiterated
08/21/26
Analysts Offer Insights on Healthcare Companies: DENTSPLY SIRONA (NASDAQ: XRAY) and Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF)
Barrington Analyst forecast on CH:DY2
Barrington
Barrington
CHF13.66CHF12.05
Buy
21.34%
Upside
Reiterated
08/10/26
Dentsply Sirona price target lowered to $15 from $17 at BarringtonDentsply Sirona price target lowered to $15 from $17 at Barrington
Robert W. Baird Analyst forecast on CH:DY2
Robert W. Baird
Robert W. Baird
CHF11.25CHF12.05
Hold
21.34%
Upside
Reiterated
08/07/26
Dentsply Sirona price target raised to $15 from $14 at BairdDentsply Sirona price target raised to $15 from $14 at Baird
Stifel Nicolaus Analyst forecast on CH:DY2
Stifel Nicolaus
Stifel Nicolaus
CHF11.25
Hold
13.26%
Upside
Reiterated
08/07/26
Stifel Nicolaus Sticks to Their Hold Rating for DENTSPLY SIRONA (XRAY)
Evercore ISI
CHF11.25
Hold
13.26%
Upside
Reiterated
08/07/26
Evercore ISI Keeps Their Hold Rating on DENTSPLY SIRONA (XRAY)
Needham
Hold
Reiterated
08/07/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Resmed (NYSE: RMD) and DENTSPLY SIRONA (NASDAQ: XRAY)
William Blair Analyst forecast on CH:DY2
William Blair
William Blair
Hold
Reiterated
08/07/26
Analysts Conflicted on These Healthcare Names: Astellas Pharma (Other OTC: ALPMF), DENTSPLY SIRONA (NASDAQ: XRAY) and IDEAYA Biosciences (NASDAQ: IDYA)
Piper Sandler Analyst forecast on CH:DY2
Piper Sandler
Piper Sandler
CHF11.25
Hold
13.26%
Upside
Reiterated
08/07/26
Piper Sandler Reaffirms Their Hold Rating on DENTSPLY SIRONA (XRAY)
BMO Capital Analyst forecast on CH:DY2
BMO Capital
BMO Capital
CHF9.64CHF10.44
Hold
5.17%
Upside
Reiterated
08/06/26
BMO Capital Keeps Their Hold Rating on DENTSPLY SIRONA (XRAY)
Morgan Stanley Analyst forecast on CH:DY2
Morgan Stanley
Morgan Stanley
Hold
Reiterated
07/24/26
Analysts Are Neutral on These Healthcare Stocks: DENTSPLY SIRONA (XRAY), Edwards Lifesciences (EW)
Leerink Partners Analyst forecast on CH:DY2
Leerink Partners
Leerink Partners
Hold
Reiterated
06/12/26
Analysts Conflicted on These Healthcare Names: United Therapeutics (NASDAQ: UTHR), DENTSPLY SIRONA (NASDAQ: XRAY) and Climb Bio (NASDAQ: CLYM)
Bank of America Securities Analyst forecast on CH:DY2
Bank of America Securities
Bank of America Securities
CHF13.66
Buy
37.52%
Upside
Reiterated
06/11/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
UBS
CHF14.46CHF13.66
Buy
37.52%
Upside
Reiterated
05/07/26
Dentsply Sirona price target lowered to $17 from $18 at UBSDentsply Sirona price target lowered to $17 from $18 at UBS
Citi
CHF8.03CHF8.43
Sell
-15.06%
Downside
Reiterated
05/06/26
DENTSPLY SIRONA (XRAY) Receives a Sell from Citi
Mizuho Securities Analyst forecast on CH:DY2
Mizuho Securities
Mizuho Securities
CHF12.85CHF11.25
Hold
13.26%
Upside
Reiterated
05/06/26
Dentsply Sirona price target lowered to $14 from $16 at MizuhoDentsply Sirona price target lowered to $14 from $16 at Mizuho
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays
CHF7.23CHF8.84
Sell
-11.01%
Downside
Reiterated
08/21/26
Analysts Offer Insights on Healthcare Companies: DENTSPLY SIRONA (NASDAQ: XRAY) and Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF)
Barrington Analyst forecast on CH:DY2
Barrington
Barrington
CHF13.66CHF12.05
Buy
21.34%
Upside
Reiterated
08/10/26
Dentsply Sirona price target lowered to $15 from $17 at BarringtonDentsply Sirona price target lowered to $15 from $17 at Barrington
Robert W. Baird Analyst forecast on CH:DY2
Robert W. Baird
Robert W. Baird
CHF11.25CHF12.05
Hold
21.34%
Upside
Reiterated
08/07/26
Dentsply Sirona price target raised to $15 from $14 at BairdDentsply Sirona price target raised to $15 from $14 at Baird
Stifel Nicolaus Analyst forecast on CH:DY2
Stifel Nicolaus
Stifel Nicolaus
CHF11.25
Hold
13.26%
Upside
Reiterated
08/07/26
Stifel Nicolaus Sticks to Their Hold Rating for DENTSPLY SIRONA (XRAY)
Evercore ISI
CHF11.25
Hold
13.26%
Upside
Reiterated
08/07/26
Evercore ISI Keeps Their Hold Rating on DENTSPLY SIRONA (XRAY)
Needham
Hold
Reiterated
08/07/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Resmed (NYSE: RMD) and DENTSPLY SIRONA (NASDAQ: XRAY)
William Blair Analyst forecast on CH:DY2
William Blair
William Blair
Hold
Reiterated
08/07/26
Analysts Conflicted on These Healthcare Names: Astellas Pharma (Other OTC: ALPMF), DENTSPLY SIRONA (NASDAQ: XRAY) and IDEAYA Biosciences (NASDAQ: IDYA)
Piper Sandler Analyst forecast on CH:DY2
Piper Sandler
Piper Sandler
CHF11.25
Hold
13.26%
Upside
Reiterated
08/07/26
Piper Sandler Reaffirms Their Hold Rating on DENTSPLY SIRONA (XRAY)
BMO Capital Analyst forecast on CH:DY2
BMO Capital
BMO Capital
CHF9.64CHF10.44
Hold
5.17%
Upside
Reiterated
08/06/26
BMO Capital Keeps Their Hold Rating on DENTSPLY SIRONA (XRAY)
Morgan Stanley Analyst forecast on CH:DY2
Morgan Stanley
Morgan Stanley
Hold
Reiterated
07/24/26
Analysts Are Neutral on These Healthcare Stocks: DENTSPLY SIRONA (XRAY), Edwards Lifesciences (EW)
Leerink Partners Analyst forecast on CH:DY2
Leerink Partners
Leerink Partners
Hold
Reiterated
06/12/26
Analysts Conflicted on These Healthcare Names: United Therapeutics (NASDAQ: UTHR), DENTSPLY SIRONA (NASDAQ: XRAY) and Climb Bio (NASDAQ: CLYM)
Bank of America Securities Analyst forecast on CH:DY2
Bank of America Securities
Bank of America Securities
CHF13.66
Buy
37.52%
Upside
Reiterated
06/11/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
UBS
CHF14.46CHF13.66
Buy
37.52%
Upside
Reiterated
05/07/26
Dentsply Sirona price target lowered to $17 from $18 at UBSDentsply Sirona price target lowered to $17 from $18 at UBS
Citi
CHF8.03CHF8.43
Sell
-15.06%
Downside
Reiterated
05/06/26
DENTSPLY SIRONA (XRAY) Receives a Sell from Citi
Mizuho Securities Analyst forecast on CH:DY2
Mizuho Securities
Mizuho Securities
CHF12.85CHF11.25
Hold
13.26%
Upside
Reiterated
05/06/26
Dentsply Sirona price target lowered to $14 from $16 at MizuhoDentsply Sirona price target lowered to $14 from $16 at Mizuho
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ODTXOdyssey Therapeutics, Inc.
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering DENTSPLY SIRONA

3 Months
Success Rate
5/14 ratings generated profit
36%
Average Return
-3.79%
Copying Kevin Caliendo's trades and holding each position for 3 Months would result in 35.71% of your transactions generating a profit, with an average return of -3.79% per trade.
1 Year
Michael PetuskyBarrington
Success Rate
4/39 ratings generated profit
10%
Average Return
-22.24%
Copying Michael Petusky's trades and holding each position for 1 Year would result in 10.26% of your transactions generating a profit, with an average return of -22.24% per trade.
2 Years
Success Rate
1/14 ratings generated profit
7%
Average Return
-29.16%
Copying Kevin Caliendo's trades and holding each position for 2 Years would result in 7.14% of your transactions generating a profit, with an average return of -29.16% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DY2 Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
0
3
4
4
1
Buy
4
2
0
0
1
Hold
10
9
8
10
11
Sell
3
4
4
3
3
Strong Sell
0
0
0
0
0
total
17
18
16
17
16
In the current month, DY2 has received 2 Buy Ratings, 11 Hold Ratings, and 3 Sell Ratings. DY2 average Analyst price target in the past 3 months is 11.35.
Each month's total comprises the sum of three months' worth of ratings.

DY2 Financial Forecast

DY2 Earnings Forecast

Next quarter’s earnings estimate for DY2 is CHF0.26 with a range of CHF0.21 to CHF0.33. The previous quarter’s EPS was CHF0.42. DY2 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year DY2 has Performed in-line its overall industry.
Next quarter’s earnings estimate for DY2 is CHF0.26 with a range of CHF0.21 to CHF0.33. The previous quarter’s EPS was CHF0.42. DY2 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year DY2 has Performed in-line its overall industry.

DY2 Sales Forecast

Next quarter’s sales forecast for DY2 is CHF695.42M with a range of CHF682.80M to CHF718.96M. The previous quarter’s sales results were CHF721.37M. DY2 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year DY2 has Performed in-line its overall industry.
Next quarter’s sales forecast for DY2 is CHF695.42M with a range of CHF682.80M to CHF718.96M. The previous quarter’s sales results were CHF721.37M. DY2 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year DY2 has Performed in-line its overall industry.

DY2 Stock Forecast FAQ

What is CH:DY2’s average 12-month price target, according to analysts?
Based on analyst ratings, DENTSPLY SIRONA Inc’s 12-month average price target is 11.35.
    What is CH:DY2’s upside potential, based on the analysts’ average price target?
    DENTSPLY SIRONA Inc has 14.27% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is DENTSPLY SIRONA Inc a Buy, Sell or Hold?
          DENTSPLY SIRONA Inc has a consensus rating of Hold, which is based on 2 buy ratings, 9 hold ratings and 1 sell ratings.
            What is DENTSPLY SIRONA Inc’s share price target?
            The average share price target for DENTSPLY SIRONA Inc is 11.35. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is CHF13.66 ,and the lowest forecast is CHF8.84. The average share price target represents 14.27% Increase from the current price of CHF9.93.
              What do analysts say about DENTSPLY SIRONA Inc?
              DENTSPLY SIRONA Inc’s analyst rating consensus is a Hold. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of DENTSPLY SIRONA Inc?
                To buy shares of CH:DY2, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.